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Abstract  
 
Purpose 
Hydrogen peroxide (H2O2) plays a vital role in normal cellular processes but at 
supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is 
potentially exploitable for the treatment of cancer in combination with radiotherapy (RT). 
We report the first Phase I trial testing the safety and tolerability of intratumoural H2O2 + 
external beam RT as a novel combination in patients with breast cancer, and exploratory 
plasma marker analyses investigating possible mechanisms of action. 
 
Methods and Materials 
12 patients with breast tumours ≥3 cm (surgically or medically inoperable) received 
intratumoural H2O2 with either 36 Gy in 6 twice-weekly fractions (n=6) or 49.5 Gy in 18 daily 
fractions (n=6) to the whole breast +/- loco-regional lymph nodes in a single-centre, non-
randomised study. H2O2 was mixed in 1% sodium hyaluronate gel (final H2O2 concentration 
0.5%) before administration to slow drug release and minimise local discomfort. The 
mixture was injected intratumourally under ultrasound guidance twice-weekly 1h prior to 
RT. The primary endpoint was patient-reported maximum intratumoural pain intensity 
before and 24h post-injection. Secondary endpoints included ≥grade 3 skin toxicity and 
tumour response by ultrasound. Blood samples were collected before, during and at the end 
of treatment for cell-death and immune marker analysis. 
 
Results 
Compliance with H2O2 and RT was 100%. 5/12 patients reported moderate pain following 
injection (grade 2 CTCAE v4.02) with median duration 60min (interquartile range 20-
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120min). Skin toxicity was comparable to RT alone, with maintained partial/complete 
tumour response relative to baseline in 11/12 patients at last follow-up (median 12 
months). Blood marker analysis highlighted significant associations of TRAIL, IL-1β, IL-4 and 
MIP-1α with tumour response. 
 
Conclusions 
Intratumoural H2O2 with RT is well-tolerated with no additional toxicity compared to RT 
alone. If efficacy is confirmed in a randomised Phase II trial, the approach has potential as a 
cost-effective radiation response enhancer in multiple cancer types where locoregional 
control after RT alone remains poor. 
 
Keywords 
Hydrogen Peroxide, Breast Cancer, Radiotherapy, Radiotherapy drug combinations 
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Introduction  
 
Breast cancer presents a global challenge, with an estimated incidence of 2 million 
worldwide, 80% of whom present with locally advanced disease (1,2). In the UK, where 
women with locally advanced disease represent a minority (7-13%) of the 55,000 new 
patient presentations, the lifetime morbidity of progressive local disease is significant (3-6). 
Treatment is challenging in frail or elderly individuals who are unfit for or refuse surgery, 
and for whom RT +/- endocrine therapy is often the most appropriate option for relief of 
breast ulceration, bleeding, and pain. Locally advanced inoperable primary or recurrent 
cancers infiltrating the breast/chest wall and/or axilla, with or without metastases, are 
typically associated with life expectancies measured in years rather than months and 
present significant challenges to patients and medical professionals. This represents an area 
of unmet clinical need, where innovative approaches to enhance response to radiation 
would be highly beneficial. 
 
An interaction at a cellular level between H2O2 and ionising radiation (IR) was first reported 
in osteosarcoma (HS-Os-1) and prostate cancer (PC-3) cell lines, which demonstrated 
extreme resistance to either H2O2 or 30 Gy alone (7,8). The addition of 0.1 mM H2O2 prior to 
IR resulted in enhanced cytotoxicity without causing DNA double strand breaks that 
classically mediate cell killing (9,10). A novel mechanism was postulated to involve 
lysosomal membrane rupture with release of powerful oxidants, including heavy metal ions 
that permeabilise mitochondria and activate apoptosis (11). In vivo use involved a mixture 
of 0.5% H2O2 in 0.83% sodium hyaluronate gel, the Kochi Oxydol-Radiation Therapy for 
Unresectable Carcinomas (KORTUC) strategy designed to minimise local pain at the 
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injection site. Intratumoural injection of this H2O2 gel mixture into murine tumours prior to 
30 Gy IR demonstrated clear evidence of growth delay above that achieved by either 
modality alone. No toxicity was noted (12).  
 
In this study we report the first systematically conducted Phase I trial testing intratumoural 
H2O2 in combination with RT in locally advanced breast cancer (NCT02757651). The primary 
objective was assessment of safety and tolerability of H2O2 injections with moderately 
hypofractionated RT. Secondary endpoints included the proportion of patients requiring 
additional pain medication, incidence of ≥ grade 3 skin toxicity, and tumour response 
assessment. Exploratory analysis of plasma markers was also performed.  
 
Materials and Methods  
 
Study design 
This non-randomised study involved patients with locally advanced or locally recurrent 
breast cancer (with or without metastases) in whom RT was indicated for loco-regional 
disease control. Patients were either inoperable due to comorbidities or local disease 
extent, or else surgery to the breast primary was not appropriate due to presence of 
metastatic disease.  
 
The single centre study was conducted at XXX (CCR4502). Approval by the Research Ethics 
Committee (REC) and the Medicines and Healthcare products Regulatory Agency (MHRA) 
was obtained prior to trial commencement (IRAS 203161, REC 16/LO/1566, EudraCT 2016-
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000833-40). Monitoring was undertaken by the Clinical Trials Unit at XXX. The trial schema is 
shown in Figure 1. 
 
Eligible patients were over 18 years of age, had histologically confirmed breast cancer, and 
required breast RT for local control and/or palliation of loco-regional symptoms. They had at 
least one breast tumour measuring ≥3 cm in diameter in a superficial location accessible for 
injection. Any combination of oestrogen receptor (ER), progesterone receptor (PR) and 
HER2 expression was allowed. Exclusion criteria included prior RT to the breast and 
concomitant biological therapies other than trastuzumab, pertuzumab and denosumab. 
Pregnancy was excluded in female patients of child-bearing age. Patients were excluded if 
the anatomical location of the breast tumour, such as proximity to blood vessels or the 
brachial plexus, precluded safe access for intratumoural injection. This precaution 
minimised the risk of injection into a blood vessel causing embolism, an adverse effect that 
this has not been described in the literature in relation to intratumoural H2O2 (13,14).  
 
Drug formulation 
 
A slow release 0.5% H2O2 solution was created by mixing 0.4 ml of 3% H2O2 (2.0 ml sterile 
ampoules supplied by Stockport Pharmaceuticals, UK) with 2.0 ml OSTENIL® (20 mg sodium 
hyaluronate in a 2.0 ml pre-loaded syringe provided by AAH Pharmaceuticals, UK), the latter 
licensed for intra-articular injection of arthritic joints (15). The low molecular weight of H2O2 
(34 g/mol) ensures rapid equilibration of drug within the gel. The mixture is a colourless, 
viscous solution (pH 6.8-7.8) stored at
 
room temperature and stable for 2 hours following 
preparation, as determined by viscosity measurements (performed by Stockport 
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Pharmaceuticals, UK). The gel allows slow release of H2O2 over at least 24 hours, as 
evidenced by generation of oxygen microbubbles upon injection, a feature that provides a 
strong rationale for twice-weekly administration during RT (16). In the trial, the drug and gel 
were mixed under aseptic conditions using two syringes connected via a 2-way tap. Once 
made up, each syringe contained 2.4 ml of 0.5% H2O2, the contents of both syringes typically 
needed for tumours measuring 30-60 mm in diameter. 
 
Radiotherapy  
 
Six patients received 49.5 Gy in 18 daily fractions of 2.75 Gy, and 6 were treated with 36 Gy 
in 6 twice-weekly fractions of 6 Gy to the whole breast ± locoregional lymph nodes. The 
equivalent RT dose expressed in conventional 2 Gy fractions (EQD2) was 57 Gy and 65 Gy for 
these two schedules respectively (Figure S1). Patients on the 6 Gy twice-weekly schedule, 
requiring lymph node irradiation in addition to the breast, were treated to a total dose of 30 
Gy in 5 twice-weekly fractions of 6 Gy to the nodal regions, in order not to exceed brachial 
plexus tolerance dose (as per standard institutional guidelines). 
 
The RT schedule was selected according to the patient’s performance status and 
comorbidities, with fitter patients selected for the daily treatment schedule. RT was 
delivered using a linear accelerator, with 6-10 MV photons, and 3D-planned using data from 
a CT planning scan, and using standard tangentially opposed fields. Patients were simulated 
and treated in the supine position on a breast board with both arms abducted. The clinical 
target volume (CTV) comprised the entire ipsilateral breast, including the deep fascia, but 
excluding underlying muscle or overlying skin (when not involved with disease). The RT dose 
7 
 
was prescribed to the 100% isodose, ensuring the target volume was within the 95%-107% 
isodose lines. Organs at risk including the heart, lung and contralateral breast were outlined 
and standard guidelines for dose tolerances followed. A standard treatment verification 
protocol was used, consisting of daily imaging for the first 3 days, and subsequent weekly 
imaging. In cases where there was skin involvement by tumour, treatment included 5 mm 
wax bolus throughout RT to maximise dose to skin, in keeping with standard practice. In 
patients treated with 49.5 Gy in 18 fractions, a sequential boost dose to the tumour bed 
(13.35 Gy in 5 daily fractions using mini-tangential opposed beams or a directly applied 
electron beam) was allowed, but this needed to be declared at time of trial entry. A tumour 
bed boost dose increased the EQD2 to that comparable with 36 Gy in 6 fractions and with 
dose intensities previously reported in earlier patient cohorts treated with the same drug 
preparation (17,18). 
 
Intratumoural injections of H2O2 in sodium hyaluronate gel  
 
Transdermal intratumoural KORTUC injections were administered twice-weekly 
commencing in the second calendar week of RT. Each patient received 4 to 6 doses in total 
(median = 5 injections), the smaller number given to patients prescribed 6 fractions. The 
rationale for starting KORTUC in the second week was to allow for reduction in tumour 
interstitial pressure during the first week of RT, enabling technically easier and more 
tolerable injections for the patient. Injections were performed (23-gauge needle) under 
ultrasound (US) guidance by a trained radiologist or radiographer after 0.5% lignocaine 
injection to anaesthetise the skin. For tumours measuring 30-60 mm in size, two syringes 
(4.8 ml) of 0.5% H2O2 in sodium hyaluronate gel was injected at each time point. Three 
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syringes (7.2 ml) were required for tumours >60 mm in size. Uniform and accurate delivery 
under US guidance via 2-3 differently angled needle tracks was aided by the immediate 
appearance of oxygen microbubbles as H2O2 degraded to oxygen and water within the 
tumour (see Figure 2A). The needle tip was positioned at the deepest aspect of the tumour 
and the gel released slowly whilst withdrawing the needle towards the surface. For smaller 
tumours, it was possible to achieve even distribution of the H2O2 gel mixture within the 
tumour via a single skin puncture site and by altering the angle of the needle (working from 
left to right or top to bottom within the tumour). For some larger tumours (for example > 60 
mm) it was necessary to inject the tumour via more than one skin entry point from different 
directions to ensure even distribution of oxygen microbubbles throughout the tumour 
volume. The number of needle tracks within the tumour and skin entry points were decided 
by the radiologist during the ultrasound scan, and guided by the extent and distribution of 
oxygen microbubbles during the injection procedure. If any gel tracked back to the skin 
surface upon withdrawal of the needle it was promptly wiped away with sterile gauze. If 
patients had >1 distinct tumour in the breast/axilla, the clinician/radiologist was required to 
clearly document the injected lesion (usually the largest) to aid response assessment. RT 
was delivered within 1-2 hours after H2O2 injection.  
 
Treatment monitoring  
 
Within each RT group (daily or twice-weekly fractions), a minimum gap of 1 week was 
stipulated between the first and second patient, during which acute toxicity data associated 
with intratumoural injections (pain, skin toxicity, and tumour lysis) was reviewed by an 
Independent Data Monitoring Committee (IDMC). Based on predetermined criteria, the 
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second and third patients in each group and subsequently the fourth, fifth and sixth patients 
in each group were allowed to be treated concomitantly.  
 
Primary endpoint 
 
This related to the timing, severity and duration of pain post-injection recorded via a self-
reported questionnaire completed by patients at home. An 11-point numerical scale ranging 
from 0 (“no pain”) to 10 (“worst possible pain”) recorded severity and duration prior to and 
over 24 hours after each H2O2 injection (Figure S1). Patient-reported scores were used to 
calculate i) the proportion of patients with pain scores ≥5 points above baseline after any of 
the intratumoural injections, and ii) the requirement for additional pain medication.  
 
Secondary endpoints 
 
Secondary endpoints included acute RT-induced skin toxicity, serum biochemistry and 
tumour response. Skin toxicity was assessed weekly in all patients during and for 4 weeks 
after RT by a member of the clinical team. Standardised proformas recorded the degree of 
erythema and desquamation of the skin of the breast. In each of the RT groups, if 
  ℎ	 one of the first 3 patients had a persistent CTCAE (v4.02) skin toxicity ≥ grade 
3 six weeks after RT, the IDMC allowed recruitment to continue for a further 3 patients 
within that RT schedule. If moist desquamation was seen beyond skin folds, weekly 
assessments were continued until severity reduced to ≤ grade 1. The proportion of patients 
with ≥ grade 3 skin toxicity at any time from the start of RT to 4 weeks post-RT, and the 
worst grade of skin toxicity reported from the start of RT to 4 weeks post RT were recorded 
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in these cases. However it was recognised that if cancer infiltrated skin, patients would 
typically experience ≥ grade 3 skin toxicity after RT alone. 
 
In every patient, routine biochemistry including serum potassium, calcium and uric acid 
were measured 2 days after the first H2O2 dose to rule out tumour lysis prior to proceeding 
with subsequent doses (19).   
 
Tumour response was assessed at 3, 6, and 12 months post-treatment. At each timepoint 3-
dimensional US measurements were obtained and the tumour volume calculated on the 
assumption that breast tumours assume a hemi-ellipsoid shape, as previously demonstrated 
(20). Maximum tumour dimension alone was not considered an accurate representation of 
tumour response especially when tumours ‘flatten’ following radiotherapy. Tumour volumes 
were compared against pre-treatment measurements applying RECIST-like principles, with 
complete response (CR) defined as disappearance of the target lesion, partial response (PR) 
as at least a 30% reduction in tumour volume, and stable disease (SD) as less than a 30% 
reduction or 20% increase in tumour volume.  
 
Statistical considerations 
 
Based on the previously published data, 30-100% patients experienced pain described as no 
worse than ‘mild’ (or CTCAE grade 1) for several hours following injection (17,21-23). A 
single case of tumour lysis syndrome (mild) was reported in a total of 139 breast cancer 
patients in the Japanese literature. Given this knowledge of the safety of H2O2 plus RT, the 
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Phase I trial required 12 patients to be recruited. Patients treated with once-daily and twice-
weekly fractions of RT were analysed as a single stratum and the study population defined 
as all patients who registered for the trial and received at least one dose of intratumoural 
H2O2. Tumour volumes were calculated using 3-dimensional measurements obtained from 
US scans. 
 
Plasma Markers  
 
Blood samples were obtained pre-RT and at the end of the first and last weeks of RT. Blood 
(two 9 ml K3-EDTA tubes) was obtained by venepuncture and processed within 30 minutes. 
Plasma and buffy coat were isolated by centrifugation at 1600 x g for 10 minutes at room 
temperature and frozen in aliquots at -80°C. All the plasma samples subsequently 
underwent one freeze-thaw cycle prior to assay. 
 
ELISA and Luminex Assay 
 
Frozen plasma samples were thawed on ice and brought to room temperature. They were 
spun at 10000 x g for 10 minutes and the plasma supernatant assayed either by ELISA or 
Luminex assay as per manufacturers’ protocols. Results were measured against a normal 
plasma control obtained from a healthy donor (Cambridge BioScience Ltd). The absorbance 
for ELISA was obtained using a POLAR star Omega plate reader spectrophotometer (BMG 
LABTECH). The Luminex Human XL Cytokine Discovery Panel (15-plex, #FCSTM18-15, R&D 
System) was carried out with a minimum of 100 events per bead using a Luminex 200 
system with xPONENT v3.1 software (Millipore). The plasma samples were assayed in 
duplicate wells for individual targets at their corresponding time-points (pre-RT, end of first 
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week of -RT and post-H2O2 + RT) and the log2 fold change calculated. Further information 
regarding the ELISA and Luminex analytes, their dilutions and kit details used in this study 
are provided in Table S1.  
 
Exploratory translational endpoints  
 
Exploratory analyses of plasma biomarkers of cell death, inflammation, and immune 
response were conducted to test feasibility of investigating novel mechanisms of action and 
biomarkers of response in trial patients. A linear mixed effect model was used to model the 
random effect of longitudinal data that the markers generated (24). The model was built to 
study the effect of each marker, and to quantify its significance in terms of association with 
tumour shrinkage over time. The difference between individual and temporal variability was 
treated as random effect. The impact of each marker was regarded as a fixed effect. The 
model used was: 
 
Tumour_volume = marker + time + marker: time + random_effect (time) 
 
The ‘:’ colon sign denotes the variation of each plasma marker with time. Each marker was 
used to fit a mixed model individually with all patient samples and 20 models were fitted in 
total. A p-value for the coefficient of each marker was calculated to indicate whether the 
fixed effect had significance (at the 5% level). All graphs were generated using Graphpad 
Prism v8.1 (Mac OS), Graphpad Software, La Jolla California USA. 
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Results 
 
Patient characteristics 
 
Patient demographics, tumour characteristics, prior treatment and RT target volumes are 
summarised in Table 1. 13 patients (11 female, 2 male) were recruited to the study between 
February 2017 and August 2018. All patients had locally advanced or recurrent breast 
cancer, and were inoperable due to co-morbidities, local extent of disease or metastatic 
disease. One patient withdrew due to clinical deterioration unrelated to the trial before 
starting RT and received no H2O2, so an additional (13
th
) patient was recruited. Median age 
was 77 years (range 45-93). Three patients were wheelchair-bound due to co-morbidities 
and frailty. Breast tumour stage was T2 in 5/12 patients and T4 in 7/12 patients. 6/12 had 
N0 and 6/12 N1 disease (axillary node involvement). 8/12 patients had distant metastases. 
Breast tumour size varied from 30 mm to 164 mm (maximum dimension). 10 patients had 
ER+/HER2- disease and 2 had triple negative disease. There were no patients with 
inflammatory breast cancer. All patients had received 1-4 previous lines of treatment for 
their breast cancer, and the majority had progressed on prior systemic treatment. Three 
patients had prior surgery for breast cancer, but had locally recurrent disease. During RT, 
7/12 patients continued taking concurrent endocrine therapy and 2/12 continued 
bisphosphonate therapy for metastatic bone disease.  
 
Compliance with treatment protocol and follow-up 
 
Compliance with H2O2 injections was 100% in all patients, including 1 with needle phobia. All 
patients received RT within the prescribed 1-2 hours of receiving the H2O2 injection, with a 
14 
 
single exception of a patient given 1 RT fraction before H2O2 injection in error. Results are 
reported at a minimum follow-up of 12 months for all patients alive at the time of reporting 
(range 2-24 months). 11 patients completed 12 months follow up, and the twelfth died of 
rapidly progressive metastatic disease just under 2 months following RT.  
 
Primary endpoint 
 
The pain scores are summarised in Table 2, with respective grades detailed in Figure S1 (iii). 
3/12 patients experienced grade 1 (mild) tumour pain post injection, and 5/12 experienced 
grade 2 pain (moderate severity, limiting activities of daily living) as per CTCAE v4.02 (25). 
The remainder did not report any additional pain following intratumoural injection. Median 
pain duration was 60 minutes with an inter-quartile range of 20-120 minutes.  
 
4/12 patients reported pain ≥5 points above baseline during treatment. One patient was 
taking opiate analgesia (oral morphine) prior to starting radiotherapy to control pain 
resulting from a fungating breast tumour. 6/12 patients required additional analgesia to 
manage their symptoms (paracetamol and codeine-based). In these cases, management 
included ensuring compliance with pre-existing painkillers and optimising analgesia +/- 
anxiolytics for the remainder of their treatment.  
 
Secondary endpoints 
 
Skin toxicity and tumour lysis 
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The highest grade of skin toxicity reported was grade 3 in 5/12, grade 2 in 4/12 patients, 
grade 1 in 1/12, and grade 0 in 2/12 patients (Table 2 and Figure S1 (iv)). All 5 patients who 
experienced grade 3 skin toxicity had been treated with bolus during radiotherapy (due to 
skin involvement by tumour). There was no suggestion of enhancement of erythema due to 
local leakage of H2O2. The acute radiation skin toxicity observed in the trial was comparable 
to that expected with standard RT alone, including in patients with cancer infiltrating 
overlying skin (26). There were no cases of tumour lysis syndrome.  
 
Tumour response 
 
Figure 2B (i) and Table S2 detail the tumour response based on US measurements at 
successive time-points post-treatment. At the last imaging assessment percentage tumour 
volume reduction was between 50 and 100% as shown in Figure 2B (ii). All evaluable 
patients in this study maintained loco-regional control in the irradiated target lesion at last 
clinical follow-up (median 12 months, range 2-24 months). Patient 12 died of metastatic 
disease 6 weeks after RT and was not evaluable at the 3-month endpoint for tumour 
response. 
 
As an illustrative example Figure 2C shows tumour extent in patient 10 pre-RT and 12 
months post-treatment (patient maintained CR at 18 months). Only 1/12 patients had >1 
distinct tumour lesions within the RT treatment volume. In this patient only the tumour 
injected with H2O2 showed maintained PR at 12 months, whereas the 2 lesions receiving the 
same RT alone showed stable disease (the non-injected lesions acting as internal controls). 
With regards to tumour response assessment, there were discrepancies in 2 patients 
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between US and clinical response assessments (Table S2). In patient 9, US measurements 
between 6 and 12 months suggested an increase in tumour size despite an excellent partial 
response on clinical examination. Radiology review of the US images at 12 months post-
treatment indicated changes consistent with fibrosis rather than active tumour. Similarly, 
patient 8 demonstrated a complete response on clinical assessment at 12 months, despite 
the presence of stable measurable disease on US. A staging PET/CT scan performed 
concurrently confirmed complete metabolic response in the H2O2 + RT-treated breast 
tumour, as shown in Figure 2D.  
 
Exploratory secondary endpoint (post-hoc analysis) 
 
10/12 patients consented to provide blood for research at the time points shown in Figure 
3A. The exploratory target panel for ELISA and Luminex assays comprised 21 markers 
involved in cell death, the immune checkpoint, chemo-attraction, immune regulation and 
angiogenesis (Table S3). Log2 transformed fold change of targets normalised to their 
baseline (pre-RT) expression were plotted for all patients, comparing levels after RT alone 
(at the end of 1
st
 week of treatment) and after H2O2 + RT (end of treatment) (Figure 3B and 
Figure S3). There was no consistent trend when comparing RT alone versus H2O2 + RT in this 
small exploratory cohort. However, upregulation of markers involved in inflammation, 
immune modulation and Damage Associated Molecular Patterns (DAMPs) was noted (27). 
Application of a linear mixed effect model identified four significant (p<0.05) associations 
with tumour shrinkage, suggesting TRAIL mediated apoptosis with increased activated T-cell 
signaling (IL-4, MIP-1α) and macrophage stimulation (IL-1β) (Figure 3C and Table S4). 
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Discussion 
 
This Phase I study raised no concerns relating to local or systemic toxicity when 
intratumoural H2O2 is delivered with RT doses per fraction up to 6 Gy in patients with locally 
advanced primary or recurrent breast cancer unsuitable for primary surgery or palliative 
debulking. The intervention is well tolerated even by the frail, older patients and those with 
needle phobia. In those patients with pre-existing pain symptoms, it was important and 
straightforward to optimise pain medication prior to starting treatment.  
 
Commencing H2O2 injections in the second calendar week of radiotherapy ensured that there 
were no technical challenges (i.e. resistance due to tissue turgor) to injecting the prescribed 
volume of drug in any of the patients. Given that H2O2 breaks down to O2 within the tumour 
(2 molecules of H2O2 degrade to 1 molecule of O2 and 2 molecules of water), it is 
hypothesised that this may contribute to reoxygenation of hypoxic areas, thereby alleviating 
radiation resistance. Therefore, aside from the classical DNA damage effects, another 
mechanism of synergy between H2O2 and RT may result from reoxygenation. This is currently 
being investigated in the laboratory setting. In tumours that do not reoxygenate 
spontaneously during fractionated RT, H2O2 is expected to be most effective after the 
second week of RT, where such tumours are likely to be enriched with hypoxic 
radioresistant subpopulations (28-30) .  
 
Acute skin toxicity was no different to that expected after the same RT alone. As predicted, 
grade 3 radiation dermatitis occurred only in those patients with tumour involving skin, when 
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a 5 mm layer of wax ‘blanket’ ensured 100% prescribed RT dose to skin instead of 
approximately 70% of prescribed dose in patients without skin involvement (31). Grade 3 
skin desquamation managed with standard supportive measures including barrier creams 
and dressings ensured complete resolution of symptoms in every case. Overall, toxicity and 
tolerability were entirely consistent with extant literature, and these Phase I data will 
contribute to an application for regulatory approval if the planned randomised Phase II study 
confirms efficacy. 
 
In view of the limitations of US in response assessment, MRI has been selected as the 
imaging modality to monitor tumour response in the forthcoming Phase II trial. In patients 
with locally advanced breast cancers treated with radiotherapy alone at equivalent doses to 
those used in this study, local control rates would be expected to be 45-57% at 3 years post-
treatment, with lower rates associated with larger tumours (32,33). Although it is impossible 
to draw conclusions on efficacy in this Phase I trial, anecdotal tumour responses are 
suggestive of enhanced anti-tumour effect. Since lifetime control of symptomatic locally 
advanced breast cancer is a major determinant of patient quality of life as well as 
survivorship, there is potential for an effective treatment to be globally beneficial, where 
women with inoperable breast cancer often have limited access to effective treatment 
(34,35). Intratumoural H2O2 injections are inexpensive and easy to administer, requiring 
minimal additional training and infrastructure. 
 
Our study has also established that circulating plasma markers can be successfully 
quantified using the ELISA and Luminex platforms, providing insights into mechanisms of cell 
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death following treatment. IR and H2O2 induce ROS, inflammatory signaling, DNA damage, 
senescence and cell death. In addition, IR can modulate the immuno-inflammatory axis 
through the generation of ROS and DAMPs (36). The wide range of potential mechanisms of 
interaction informed the choice of 21 markers in our exploratory panel.  
 
The effect of H2O2 within the cell is concentration dependent; having a role in signalling and 
homeostasis at nanomolar concentrations (nM) and triggering cell death at 
supraphysiological (mM) concentrations (37). The physiological outcome within the cell is 
modulated by antioxidant enzymes such as catalases, peroxidases and thioredoxin-linked 
systems (38). By affecting protein kinases and phosphatases, H2O2 influences a number of 
signaling cascades including ERK, JNK, MAPK, p38, TNFα, NFκB, IL-1β, IL-6, IL-8, MCP-1 and 
MIP (37,39,40). Several publications have demonstrated apoptosis as the principal mode of 
cell death following H2O2 treatment (11,41-43). The intrinsic mitochondrial pathway is 
thought to be the predominant mechanism of apoptosis (44). One study reported apoptosis 
induction following exposure to H2O2 levels <0.4 mM and upregulation of RIP, a gene 
associated with necrosis, at higher concentrations (45). Exposure to H2O2 can result in 
increased expression of inflammatory cytokines (46). IL-1 is a key mediator of T-cell and 
dendritic cell (DC) function. Increased IL-1α levels occur in cells undergoing necrosis, 
whereas IL-1β signals towards apoptosis (47,48). Another study reported that treating 
murine splenic T-cells with H2O2 resulted in a significant increase in IL-4 production, a key 
regulator of humoral and adaptive immunity (49). Both IL-1β and IL-4 were significantly 
associated with tumour shrinkage in our study. 
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In our plasma analysis, a significant association between TRAIL and tumour shrinkage was 
also found. Intracellular ROS such as H2O2 are thought to mediate apoptosis via death 
receptor ligands such as TRAIL (44). A study in an astroglial cell line demonstrated an 
increase in TRAIL gene expression in cells treated with H2O2 in a dose-dependent manner up 
to a concentration of 0.8 mM (50). TRAIL-dependent apoptosis regulates the priming of 
CD8
+
 memory T-cells by CD4
+
 TH1 cells (51). In a study using a murine macrophage cell line 
(B10R), exposure to H2O2 increased the transcription of the chemokines MIP-1α, MIP-1β, 
MIP-2 and MCP-1 (52). MIP-1β was undetectable in 7/10 patients but MIP-1α expression 
was detected to a varying degree in all cases, suggesting activation of CD8
+
 T lymphocytes. 
In summary, the analyisis of blood biomarkers showed correlations with clinical tumour 
response and suggest an inflammatory/immune response associated with apoptotic cell 
death. These mechanisms of action are potentially relevant to an interaction between IR 
and drug. However, in this cohort, all of whom received H2O2 + RT, it is difficult to 
distinguish the contribution of H2O2 over and above that of RT alone. The plasma analyses 
have been valuable in informing the selection of markers to investigate in a subsequent 
trial.  
 
In conclusion, the results from this Phase I trial confirm intratumoural H2O2 in combination 
with RT is a safe and simple intervention with the potential for high global impact if efficacy is 
confirmed in the forthcoming randomised Phase II trial. Proof of concept in breast cancer 
could lead to rapid evaluation in other challenging and accessible primary sites, including 
cancers of the head and neck, cervix uteri and soft tissue sarcomas, where loco-regional 
control with RT alone is poor. 
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Figure Legends 
 
Figure 1. Phase I trial schema 
A non-randomised study design testing intratumoural H2O2 in sodium hyaluronate gel in 
combination with two radiotherapy fractionation schedules in patients with locally 
advanced breast cancer, and corresponding follow up schedule. #- radiotherapy fraction; 
US- ultrasound; RT- radiotherapy. 
 
Figure 2. Intratumoural H2O2 administration and tumour response  
(A) Sequence of ultrasound images of a breast tumour showing H2O2 administration, red 
arrow indicating (i) Needle entering under ultrasound guidance (ii) H2O2 + sodium 
hyaluronate gel mixture being injected intratumourally (iii) Breakdown of H2O2 with 
formation of echogenic oxygen microbubbles (white) within the tumour (B) Tumour volume 
changes (i) Box plot showing the cumulative fold decrease (log2 transformed) for all 12 
patients, at the indicated time points post-RT (ii) waterfall plot showing % tumour volume 
change up to 12 months post-RT normalized to baseline tumour measurement (data 
represent tumour measurements at  9 and 12 months post-RT for 3 and 8 patients 
respectively). (C) Clinical photographs of patient 10 (i) Left breast with fungating tumour 
(baseline) (ii) 12 months post-treatment with H2O2 + RT. (D) 
18
F-FDG PET scans of patient 8 
(i) High tracer uptake in left breast tumour at baseline (ii) Complete metabolic response at 
12 months post-treatment. 
 
Figure 3. Analysis of Phase I trial plasma markers 
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(A) Scheme showing clinical imaging and blood sampling performed in this study. #-
radiotherapy fraction (B) Box & Whisker plot depicting log2 transformed fold change of 
analysed targets from individual patients. Values are normalized to their baseline expression 
for all 21 targets. (C) Plot shows the significant markers associated with tumour volume 
shrinkage, with multi-comparison adjusted p-value < 0.05. The bar shows the fixed effect of 
each marker with error bars, ranked by p values. A negative coefficient means that the 
marker is positively correlated with tumour shrinkage.  
 
Table Legends 
 
Table 1.  Summary of patient demographics, tumour characteristics, previous lines of 
treatment and RT treatment volumes. Patients 1, 3, 4, 5, 11 and 13 received 36Gy/6 
fractions, and 2, 6, 8, 9, 10 and 12 received 49.5Gy/18 fractions. *Performance status 
(Eastern Cooperative Oncology Group) 
 
Table 2.  Summary of pain scores and RT acute skin toxicity scores 
Pain intensity scored from 0-10 via patient self-assessment questionnaires (median 
calculated from difference in pain score pre- and post-H2O2 injection for each patient 
throughout treatment course (4-6 injections in total for each patient)); RT acute skin toxicity 
scored from 0-5 using CTCAE V4.02 by clinicians 
*patient with needle phobia; 
¶
patient had significant breast pain prior to H2O2 injection and 
poor compliance with analgesia; ¥ patient with significant breast pain and was taking opiate 
analgesia prior to RT, explaining the pain score of 0. ADL – Activities of daily living.  
 
  
 
Patient Age Sex 
PS* 
(ECOG) 
 
Baseline 
TNM 
stage 
Tumour 
Phenotype 
Prior treatment 
(no. of lines of 
therapy) 
RT target 
volume 
1 77 F 1 T2N1M1 ER
+
/HER2
-
 
Endocrine(3) 
 
Breast + axillary 
LN levels I-IV 
2 69 F 0 T4N0M1 ER
+
/HER2
-
 Endocrine(2) Breast 
3 79 F 3 T4N0M0 ER
+
/HER2
-
 Endocrine(3) Breast 
4 80 M 2 T4N0M0 ER
+
/HER2
-
 Endocrine(2) Breast 
5 89 F 3 T2N0M0 ER
+
/HER2
-
 Endocrine(1) Breast 
6 78 F 2 T4N1M1 ER
+
/HER2
-
 
Endocrine(2) 
Chemotherapy(1) 
Breast + axillary 
LN levels I-IV 
8 53 M 0 T2N0M1 ER
-
/HER2
-
 
Surgery 
Endocrine(3) 
Chemotherapy(4) 
RT (contralateral) 
Breast 
9 53 F 2 T2N1M1 ER
+
/HER2
-
 
Surgery 
Endocrine(3) 
Chemotherapy(2) 
RT (contralateral) 
Breast + axillary 
LN levels I-IV 
10 45 F 0 T4N1M1 ER
+
/HER2
-
 
Chemotherapy(1) 
 
Breast + axillary 
LN levels I-IV 
11 75 F 3 T4N1M1 ER
+
/HER2
-
 
Surgery 
Endocrine(3) 
 
Breast 
12 45 F 1 T4N1M1 ER
-
/HER2
-
 Chemotherapy(2) 
Breast + axillary 
LN levels I-IV 
13 93 F 3 T2N0M0 ER
+
/HER2
-
 None Breast 
 
 
Table 1.  Summary of patient demographics, tumour characteristics, previous lines of 
treatment and RT treatment volumes. Patients 1, 3, 4, 5, 11 and 13 received 36Gy/6 fractions, 
and 2, 6, 8, 9, 10 and 12 received 49.5Gy/18 fractions. *Performance status (Eastern 
Cooperative Oncology Group). 
  
 
Patient 
number 
Maximum pain 
intensity Extra 
analgesia 
required 
Median 
difference in 
pain score 
(pre- and post 
RT) 
Effect of pain 
on ADLs 
Maximum 
RT acute 
skin toxicity 
score 
Bolus 
during 
RT Score Period 
1 4 2 hrs N 3 
Y- housework, 
shopping 
3 Y 
2 0 0 mins N 0 N 3 Y 
3 3 30 mins N 2.5 N 2 N 
4 4 30 mins Y 0.5 N 2 N 
5 0 0 mins N 0 N 0 N 
 6* 10 6 hrs Y 5 N 1 N 
 8
†
 10 6 hrs Y 6 Y-driving 2 N 
9 6 5 hrs N 4 N 2 N 
10 8 2 hrs Y 7 Y-housework 3 Y 
11 0 0 mins N 0 N 3 Y 
 12
‡
 0 0 mins Y 0 N 3 Y 
13 6 1 hr Y 5 N 0 N 
 
 
 
Table 2.  Summary of pain scores and RT acute skin toxicity scores 
Pain intensity scored from 0-10 via patient self-assessment questionnaires (median calculated 
from difference in pain score pre- and post-H2O2 injection for each patient throughout 
treatment course (4-6 injections in total for each patient)); RT acute skin toxicity scored from 
0-5 using CTCAE V4.02 by clinicians 
*patient with needle phobia; †patient had significant breast pain prior to H2O2 injection and 
poor compliance with analgesia; ‡patient with significant breast pain and was taking opiate 
analgesia prior to RT, explaining the pain score of 0. ADL – Activities of daily living.  
Patients consented  
(n=13)
Before Radiotherapy
Baseline US tumour measurement
Biochemistry (Serum potassium, calcium, uric acid)
Blood for research (optional)
Withdrew due to 
clinical deterioration
(n=1) Treatment
H
2
O
2
 + Radiotherapy
(n=12)
49.5 Gy / 18# daily + twice weekly
H
2
O
2
 injections starting week 2 (n=6)
Blood test: end of 1st and last week of RT
Pre- and post-injection pain questionnaires
36 Gy / 6# twice weekly + twice weekly 
H
2
O
2
 injections starting week 2 (n=6)
Blood test: end of 1st and last week of RT
Pre- and post-injection pain questionnaires
Follow up
Skin toxicity weekly during RT and for 4 weeks post-RT
Tumour control: Clinical assessments 3-monthly x 24 months
US 3, 6, 12, 18 and 24 months
Figure 1







